Expression of BCL11A in chronic lymphocytic leukaemia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      CHRONIC lymphocytic leukemia; PROTEINS; REVERSE transcriptase polymerase chain reaction; RESEARCH; MONONUCLEAR leukocytes; B cell lymphoma; GENE expression; COMPARATIVE studies; RESEARCH funding; MESSENGER RNA; TRANSCRIPTION factors; STATISTICAL correlation
    • Abstract:
      Introduction: The B‐cell lymphoma/leukaemia 11A (BCL11A) gene encodes a Krüppel‐like transcription factor involved in lymphocyte development during normal haematopoiesis. Aberrant expression of BCL11A has been observed in several haematological malignancies, including chronic lymphocytic leukaemia (CLL). However, its functions in the regulatory networks of malignant B lymphocytes are poorly understood, as are the relations to clinical course and outcome of B‐cell malignancies, particularly CLL. Methods: The expression of BCL11A was analysed in peripheral blood mononuclear cells of 87 newly‐diagnosed CLL patients by quantitative reverse‐transcriptase polymerase chain reaction (qRT‐PCR), and association with clinical and molecular variables was assessed. Results: BCL11A was significantly overexpressed in CLL samples compared to control samples (p < 0.001). BCL11A expression level exhibited no association with age, sex, leukocyte, lymphocyte and platelet counts, haemoglobin level, serum β2‐microglobulin, CD38 status and cytogenetic abnormalities. On the other hand, high BCL11A expression was associated with low serum lactate dehydrogenase (p = 0.031), Binet A stage (p = 0.047) and mutated IGHV (p = 0.028). In addition, a positive correlation with BCL2/BAX mRNA ratio was observed (r = 0.36; p < 0.001). Regarding the association with the time to first treatment (TTFT), a trend towards longer median TTFT in BCL11A high‐ versus BCL11A low‐expressing cases was detected (21 vs. 6 months; p = 0.164). Conclusion: The results of this study show that BCL11A is upregulated in CLL patients, and that high BCL11A expression at diagnosis may be associated with better prognosis. These data are consistent with the role of BCL11A expression in CLL biology, and imply its potential prognostic relevance. [ABSTRACT FROM AUTHOR]